Characterization of TNG348: A Selective, Allosteric USP1 Inhibitor That Synergizes with PARP Inhibitors in Tumors with Homologous Recombination Deficiency

Antoine Simoneau(Tango Therapeutics (United States)), Scott Throner(Tango Therapeutics (United States))

Molecular Cancer Therapeutics

January 31, 2025

10.1158/1535-7163.mct-24-0515

Cited by 17

Related Papers

No related papers found

Powered by citation graph analysis